In The Press

Developing a Potent Microtubule-Targeting Agent with Less Toxicity

Diazon Pharmaceuticals is developing DZ-2384, which targets a proven therapeutic pathway in oncology, but with less toxicity than existing agents, as demonstrated in a preclinical study published November 2016 in Science Translational Medicine by researchers at McGill University in Canada.

Microtubule-Straightening Compound Widens the Therapeutic Window

Nature Reviews Drug Discovery highlights DZ-2384 as a noteworthy novel microtubule targeting agent that has potent antitumour activity in several different cancer models, but does not induce neurotoxicity at effective doses

Novel microtubule-targeting agent largely avoids neuropathy

In cancer therapy, chemotherapy is the workhorse to immunooncology’s and targeted therapy’s show horses. “There has not been a lot of innovation” in the area of chemotherapy, Gordon Shore told BioWorld Insight. Partly, he said, there are good reasons for the attention lavished on immuno-oncology and targeted therapies. The pathways targeted by those approaches “are where the underlying biology of cancer lies, and where rational intervention makes a lot of sense.” But chemotherapies remain both a market opportunity and an area in need of innovation.

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity

Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock M, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A.  The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity, Science Translational Medicine, 2016 Nov 16;8(365):365ra159. For complete article see www.ltdmcgill.ca under “Publications”.